About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...

Pritelivir Phase 2 results supported FDA Breakthrough Therapy Designation and informed the pivotal study design, which recently culminated in positive Phase 3 topline results Phase 1 results for ...

Traws Pharma, Inc. (($TRAW)) announced an update on their ongoing clinical study. Study Overview: Traws Pharma, Inc. is conducting a Phase 1 ...

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired ...

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets ...

CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled A Phase 1, ...

SCYNEXIS Inc. (NASDAQ: SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS ...

EV25 was generally well-tolerated and demonstrated a good safety profile, with no observable dose-dependent safety trends.